All In Biotech

Drug Trial Radar · NCT02919761

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease Despite Dual-DMARD Treatment

Last checked: Nov 19, 2026Latest source record: Mar 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 259 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

259

Actual

Start

Nov 7, 2016

Primary completion

Oct 17, 2018

Study completion Feb 13, 2019

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Sep 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study to examine the effect of Acthar Gel in adult participants with rheumatoid arthritis (RA) with persistently active disease even after receiving two other treatments intended to modify the disease. Part 1 is an Open Label Period in which all eligible participants receive Acthar Gel for 12 weeks. After these 12 weeks of treatment with Acthar Gel, participants will be evaluated for treatment response using the DAS28-ESR. Participants who have achieved low disease activity (LDA) will enter a double-blind randomized maintenance period (Part 2) and be randomized in a 1:1 ratio to receive either Acthar Gel or matching placebo for an additional 12 weeks. A single participant might be involved in the trial for as many as 32 weeks.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • Acthar GelDrug

    80 Units Acthar Gel per 1 mL for subcutaneous injection

  • PlaceboDrug

    Matching placebo 1 mL for subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Low Disease Activity (LDA) by VisitTime frame: Baseline to Week 12
  2. Part 2: Number of Participants Who Maintained Low Disease Activity by VisitTime frame: Week 12 to Week 24

Locations

59 sites in 5 countries. Site status is shown where the registry gives one.

  • East Bay Rheumatology Medical Group

    San Leandro, California

  • Inland Rheumatology Clinical Trials

    Upland, California

  • Orthopedic Research Institute

    Boynton Beach, Florida

  • Clinical Research of West Florida

    Clearwater, Florida

  • Southeastern Integrated Medical, PL, d/b/a Florida Medical Research

    Gainesville, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • Homestead Associates in Research

    Homestead, Florida

  • Pharmax Research Clinic

    Miami, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • San Marcus Research Clinic

    Miami Lakes, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Omega Research Consultants-DeBary

    Orlando, Florida

  • Millennium Research

    Ormond Beach, Florida

  • Clinical Research of West Florida

    Tampa, Florida

  • Arthritis & Rheumatology of Georgia, PC

    Atlanta, Georgia

  • Arthritis Research and Treatment Center

    Stockbridge, Georgia

  • Arthritis and Diabetes Clinic, Inc.

    Monroe, Louisiana

  • June DO, PC

    Lansing, Michigan

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska

  • DJL Clinical Research

    Charlotte, North Carolina

  • Columbia Arthritis Center

    Columbia, South Carolina

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Ramesh C. Gupta, MD

    Memphis, Tennessee

  • Northwest Med Care

    Cypress, Texas

  • Rheumatic Disease Clinical Research Center

    Houston, Texas

  • Accurate Clinical Research

    Houston, Texas

  • Laila Hassan, MD, PA

    Houston, Texas

  • Pioneer Research Solutions

    Houston, Texas

  • Southwest Rheumatology Research

    Mesquite, Texas

  • Sun Research Institute

    San Antonio, Texas

  • Centro Polivalente de Asistencia e Investigación Clínica CER San Juan

    San Juan, Argentina

  • Aprillus Asistencia e Investigación

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • DIM Clínica Privada

    Ramos Mejía, Buenos Aires, Argentina

  • Centro de Investigaciones Reumatológicas

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

    Durango, Mexico

  • Phylasis Clinicas Research S de RL de CV

    Estado de México, Mexico

  • SMIQ

    Querétaro, Mexico

  • Centro de Atención e Investigación Cardiovascular del Potosí, S.C.

    San Luis Potosí City, Mexico

  • INBIOMEDYC Toluca

    Toluca, Mexico

  • Unidad de Enfermedades Reumaticas y Cronico Degenerativas

    Torreón, Mexico

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.